Epygenix
Clinical trials sponsored by Epygenix, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise for rare, severe childhood epilepsy Results expected Nov 2026 (estimated)
- New hope for dravet syndrome: phase 3 trial of EPX-100 aims to cut seizures Results expected Apr 2027 (estimated)
-
New drug shows promise for rare, severe childhood epilepsy
Disease control Recruiting nowThis study tests whether clemizole HCl (EPX-100) can safely reduce seizures when added to current treatments for Lennox-Gastaut syndrome, a severe form of epilepsy. About 260 children and adults aged 2 to 55 will receive either the drug or a placebo. The main goal is to measure c…
Phase 3 • Sponsor: Epygenix • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for dravet syndrome: phase 3 trial of EPX-100 aims to cut seizures
Disease control Recruiting nowThis study tests an experimental drug called EPX-100 (clemizole) in 150 children and adults with Dravet syndrome, a severe form of epilepsy. The goal is to see if adding EPX-100 to current treatments can safely reduce the number of motor seizures. Participants will be randomly as…
Phase 3 • Sponsor: Epygenix • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC